This is a working overview of thymosin beta-4 fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
==== Police investigation ==== After the high-profile case of Madeleine McCann, that garnered attention to the kidnappings of children in Portugal, the Mendonça case received another investigation team. That team had a terrible performance, with Mendonça's family asking for the team's replacement. The leads that connected Mendonça to the international networks of pedophilia were closed in 2011. According to Cândida Almeida, of the Central Department of Investigation and Penal Action (DCIAP), there was not any more evidence and everything of this line of investigation was investigated to "exhaustion". Another reason for the closing of this line of investigation, was that the Public Prosecution considered there were "enough evidence" to accuse Dias. The DCIAP entered the case in September 2003. That new team moves forward, with one of the working theories being that Mendonça accidentally had an epileptic attack while he was with Dias. In 2019, Hernâni Carvalho interviewed Carlos do Carmo, an old investigation coordinator of PJ in Linha Aberta, of SIC. Carlos do Carmo stated that the case should have been immediately have been declared as a kidnapping, because the child followed a routine when he disappeared. He added that the bicycle and the place where it was found in the day of the disappearance should have been examined, which did not happen since it was a missing person case. They looked for Mendonça's bicycle, but they did not find it.
==== Belief systems ==== Several different and sometimes conflicting belief systems emerged regarding acupuncture. This may have been the result of competing schools of thought. Some ancient texts referred to using acupuncture to cause bleeding, while others mixed the ideas of blood-letting and spiritual qi energy. Over time, the focus shifted from blood to the concept of puncturing specific points on the body, and eventually to balancing Yin and Yang energies as well. According to David Ramey, no single "method or theory" was ever predominantly adopted as the standard. At the time, scientific knowledge of medicine was not yet developed, especially because in China dissection of the deceased was forbidden, preventing the development of basic anatomical knowledge. It is not certain when specific acupuncture points were introduced, but the autobiography of Bian Que from around 400–500 BC references inserting needles at designated areas. Bian Que believed there was a single acupuncture point at the top of one's skull that he called the point "of the hundred meetings." Texts dated to be from 156 to 186 BC document early beliefs in channels of life force energy called meridians that would later be an element in early acupuncture beliefs. Ramey and Buell said the "practice and theoretical underpinnings" of modern acupuncture were introduced in The Yellow Emperor's Classic (Huangdi Neijing) around 100 BC. It introduced the concept of using acupuncture to manipulate the flow of life energy (qi) in a network of meridian (channels) in the body.
Plastic Pasteur pipettes, also referred to as transfer pipettes, have their stems and bulbs in the form of a single piece made of soft plastic such as polyethylene. The bulb portion is thinner and therefore "squeezable", while the pipette portion is thick enough to be rigid. They commonly come in 1, 2, 3, and 5 ml which comes with a specific drop size of 10, 20, 25, 35, and 50 μL. The volumes are usually marked on the stem, though the markings are rather crude and are not particularly accurate. A plastic dropper is relatively inexpensive and disposable, so they are often used to avoid cross-contamination. In a solution containing cells or protein, it reduces the loss of cell or protein that binds to glass. Some plastic pipettes include a long flexible tube that can be bent for drawing solution from small volume tubes. Plastic Pasteur pipettes are often used in biology where most media are aqueous and solvent resistance is not important. (Most organic solvents, such as hexane and acetone cannot be used in plastic Pasteur pipettes as the solvent can dissolve the plastic.) The pipettes are also hard to wash and are usually discarded with other biohazard waste after one use. Plastic bulb pipettes are generally not precise enough to be used for exact measurements, whereas their glass counterparts can be extremely precise.
Sources: en.wikipedia.org
Signs and symptoms which (a) are suggestive of a connective tissue disease, but (b) do not meet the criteria of any defined connective tissue diseases, and (c) have lasted for at least three years. (Note, if less than three years, may be regarded as early UCTD). Positive ANA test on two different occasions.
==== Cannabinoid-based pharmaceuticals ==== Nabiximols (Sativex) is an aerosolized mist with a near 1:1 ratio of CBD and THC, used for multiple sclerosis-related pain and spasticity. Dronabinol (Marinol, Syndros) and nabilone (Cesamet) are synthetic THC analogs for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting. CBD drug Epidiolex is approved for Dravet syndrome and Lennox–Gastaut syndrome.
In homolytic cleavage, or homolysis, the two electrons in a cleaved covalent bond are divided equally between the products. This process is also known as homolytic fission or radical fission. The bond-dissociation energy of a bond is the amount of energy required to cleave the bond homolytically. This enthalpy change is one measure of bond strength. The triplet excitation energy of a sigma bond is the energy required for homolytic dissociation, but the actual excitation energy may be higher than the bond-dissociation energy due to the repulsion between electrons in the triplet state.
SIMS and FAB are quite similar. SIMS uses an ion beam, usually Ar+ or Cs+. FAB uses a neutral atom beam, usually Ar or Xe. For SIMS and FAB, if the matrix compound is more acidic than the analyte, then predominantly (M + H)+ forms formed, and conversely (M − H)−. Also possibly forming (M + Na)+, (M + K)+, etc, if the matrix is contaminated incidentally (adventitiously) by sodium, potassium, etc. Typical matrix materials include glycerol, thioglycerol, 3-nitrobenzyl alcohol, diethanolamine, triethanolamine, and dithiothreitol-dithioerythritol mixture. They are usually used to analyze polypeptides and oligonucleotides up to 20 kDa. MALDE uses a photon beam, usually the soft-UV 337 nm nitrogen laser. It can also use an infrared (IR) laser for direct analysis of samples contained in gels or thin-layer chromatography (TLC) plates. MALDE can analyze small polymers (~1 kDa), to oligosaccharides, oligonucleotides and polypeptides, antibodies, up to small proteins (~300 kDa). It is highly sensitive, requiring only femtomoles of sample. Desorption/ionization on silicon (DIOS) is similar to MALDE, but without the matrix. The sample is deposited directly on a nanostructured (porous silicon) surface and the sample desorbed directly from the nanostructured surface through the adsorption of laser light energy. DIOS has been used to analyze organic molecules, metabolites, biomolecules and peptides, and, ultimately, to image tissues and cells.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.